Venetoclax has durable clinical activity in patients with relapsed / refractory chronic lymphocytic leukemia whose disease progressed during or after
ibrutinib therapy.
«Reasons for
ibrutinib therapy discontinuation in patients with chronic lymphocytic leukemia.»
«This single - institution experience with ibrutinib confirms it to be an effective therapy and identifies, for the first time, baseline factors associated with
ibrutinib therapy discontinuation.
Jennifer A. Woyach, M.D., of Ohio State University, Columbus, and coauthors described the characteristics of patients who discontinued
ibrutinib therapy and their outcomes in a group of 308 patients participating in four trials at a single institution.
Not exact matches
In March 2016, Penn researchers published a study in Blood that showed long - term
ibrutinib treatment reverses the dysfunction of T cells in CLL and that combining CAR
therapy with
ibrutinib enhanced engineered T cell proliferation in mice.
The new data builds off several preclinical studies supporting the use of
ibrutinib with CAR
therapy.
Longer follow - up will reveal the durability of these results, the authors said, and may support the evaluation of a first - line approach with
ibrutinib and CAR
therapy in an effort to remove the need for chronic
therapy.
The US Food and Drug Administration (FDA) recently approved the oral Bruton tyrosine kinase (BTK) inhibitor
ibrutinib for the treatment of patients with relapsed or refractory marginal zone lymphoma who require systemic
therapy and have had at least one prior anti-CD20
therapy.
FDA Approved
Ibrutinib for Relapsed, Refractory Marginal Zone Lymphoma: Approval for the use of
ibrutinib in patients with relapsed or refractory marginal zone lymphoma was granted by the US Food and Drug Administration for those patients who require systemic
therapy who were treated with at least one anti-CD20
therapy.